ALC-0159 is a PEGylated lipid excipient. It can combine with ALC-0315, cholesterol and DSPC to form lipid nanoparticles for delivery and entrapment of mRNA vaccines. Currently, ALC-0159, as a helper lipid approved for RNA therapies clinically, has been applied in the research on the mRNA (COVID-19) vaccine. Besides, it is also one of the vector components in the BNT162b vaccine against COVID-19.
| Product Name | ALC-0159 |
| Chemical Name | 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide |
| CAS No. | 1849616-42-7 |
| NMPA CDE registration no. | / |
| USFDA DMF No. | / |
| Quality grade | Reagent grade |
| Quality standards | manufacturer's standard |
| Molecular Formula | C31H63NO2(C2H4O)n, n≈45 |
| Applications and examples | This product is a PEG/lipid conjugate (PEGylated lipid), mainly N,N-dipyridinamide of 2-hydroxyacetic acid which is O-PEGylated to a 2-KDa polyethylene glycol chain. It is a non-ionic surfactant that can bind with other lipids to form lipid nanoparticles for the delivery of mRNA-based vaccines. |
| Product code | O02009 |
| Package sizes | 1g |
| Storage condition | The product should be transported in a refrigerator, protected from light (for less than 2 weeks). It should be stored at -20 ± 5℃ in an inert atmosphere, protected from light. To avoid water absorption, naturally warm up to room temperature before unpacking. It is valid for 1 year when used and stored properly. |
/
ALC-0159 is a polyethylene glycol (PEG)-lipid conjugate which can prevent elimination in vivo, thus extending the circulation time of the LNP delivery system.
If you have any questions, please don't hesitate to contact us. We're always here to help with Pharmaceutical Excipients for your business. We can provide products ranging from grams to tons. AVT is able to produce and even register the product in US FDA according to your special needs.
